Abstract
Cryopreservation of ovarian tissue for fertility preservation should preferably be performed before the start of anti-cancer therapy. For many patients, however, ovarian tissue preservation is offered after some form of gonadotoxic medication has already been administered. Further, in cases of recurrent malignancies the ovarian tissue may not have been cryopreserved after the initial diagnosis. In this case study, we analyzed the viability of ovarian tissue collected for fertility preservation purposes from a 10-year-old Ewing sarcoma patient after chemotherapy.
Get full access to this article
View all access options for this article.
